Hanmi Pharmaceutical Company Limited: Diabetes Mellitus, Type 2 trials

The registry lists 10 Diabetes Mellitus, Type 2 studies with Hanmi Pharmaceutical Company Limited as lead sponsor. 2 are open to participants now and 1 have results posted.

Phase 1 4Phase 2 4Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate HM15275 in Subjects With Type 2 Diabetes MellitusRecruitingNCT07527650Phase 2
• A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinRecruitingNCT07379333Phase 3
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseCompletedNCT03353350Phase 3Results posted
• Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes MellitusStatus unknownNCT03332849Phase 1
• Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes MellitusTerminatedNCT03332836Phase 1
• Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedNCT02081118Phase 2
• A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownNCT02059564Phase 1
• Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedNCT02057172Phase 2
• A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460ACompletedNCT01724814Phase 1
• Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusCompletedNCT01452451Phase 2